- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Bimekizumab cost effective treatment option for psoriatic arthritis
![Bimekizumab cost effective treatment option for psoriatic arthritis Bimekizumab cost effective treatment option for psoriatic arthritis](https://medicaldialogues.in/h-upload/2022/08/18/750x450_183587-arthritis.webp)
In a recent study from the Swedish healthcare system perspective, assessed the cost-effectiveness of Bimekizumab, a novel inhibitor of IL-17F and IL-17A, for the treatment of psoriatic arthritis (PsA). The outcomes of the study were published in The Journal of Medical Economics. This chronic inflammatory disease affects the joints and skin, and finding cost-effective treatments is crucial.
The study, conducted using a Markov model, simulated the clinical journey of PsA patients who were either new to biologic disease-modifying antirheumatic drugs (bDMARD) or had prior experience with tumor necrosis factor inhibitors (TNFi). The research took a lifetime perspective, considering various factors, including the achievement of specific treatment responses, changes in disability index scores, and drug costs.
Results from this comprehensive analysis indicated that Bimekizumab outperformed several other treatments in terms of quality-adjusted life years (QALYs). In bDMARD-naïve patients, Bimekizumab showed greater QALYs compared to most treatments, except for infliximab. It also proved to be cost-effective when compared to various treatments, with the exception of adalimumab biosimilar. In TNFi-experienced patients, Bimekizumab led to higher QALYs compared to all comparators except certolizumab pegol and was cost-effective against numerous other treatments, including IL-17A, IL-23, and JAK inhibitors.
Despite some limitations in the study, such as the use of network meta-analysis for effectiveness estimates, the research provides valuable insights into the cost-effectiveness of Bimekizumab in treating PsA. Notably, Bimekizumab demonstrated its cost-effectiveness in Sweden, making it a promising option for patients, especially those with prior TNFi exposure.
The findings of the study have significant implications for PsA patients and healthcare systems in Sweden, suggesting that Bimekizumab may offer an effective and economically viable treatment option. As Psoriatic Arthritis continues to affect individuals globally, cost-effective and efficient treatment solutions are essential. Bimekizumab's success in this study paves the way for potential changes in PsA treatment strategies, offering newfound hope for patients in Sweden and beyond.
Source:
Sigurdardottir, V., Engstrom, A., Berling, P., Olofsson, T., Oldsberg, L., Sadler, S., Parra-Padilla, D., Melis, L., & Willems, D. (2023). Cost-effectiveness analysis of bimekizumab for the treatment of active psoriatic arthritis in Sweden. In Journal of Medical Economics (Vol. 26, Issue 1, pp. 1190–1200). Informa UK Limited. https://doi.org/10.1080/13696998.2023.2259609
Neuroscience Masters graduate
Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751